•  

News - Page 30 of 38 - TIAP

DLVR: Using personalized medicine and nature’s cellular toolkit to target cancer tumours

Every six weeks, MaRS Innovation's marketing and communications manager writes a guest post for the MaRS Discovery District blog profiling MI's activities or one of our start-up companies. This post coincided with World Cancer Day. What if you could use a cancer tumour’s proteomic profile to make it easier to target and destroy? Targeting specific proteins on the surface of individual tumours—or, more precisely, targeting a cell receptor that naturally allows substances to pass into a cell—would allow clinicians to more effectively deliver ... Read more

University of Toronto Early-Stage Technology Program (UTEST) opens applications for second start-up company cohort

Students, faculty and recent alumni with software ideas must apply by Feb. 22 Got a killer software-based idea? Are you passionate about turning that idea into a start-up company? If you’re a current student, faculty member or recent graduate of the University of Toronto, consider applying to the University of Toronto Early-Stage Technology (UTEST) program. Applications are now closed. Stay tuned for the third UTEST application call. Created as a pilot in 2012 to help the U of T community bring their software-based ideas to ... Read more

OCE invests $250,000 in ScarX Therapeutics’ revolutionary anti-scarring medication

TORONTO, ON (Jan. 24, 2013) - ScarX Therapeutics, a start-up company commercializing a groundbreaking treatment to dramatically reduce post-operation scarring, is receiving a $250,000 investment from Ontario Centres of Excellence. This story was covered in Yonge Street Media on January 30, 2013. ScarX, a topical medication, emerged from Dr. Benjamin Alman's research. Alman, head of orthopedic surgery at the Hospital for Sick Children, is developing his invention in conjunction with MaRS Innovation. Each year, doctors worldwide perform 240 million surgeries. Currently, no clinically-proven prescription ... Read more

Globe and Mail and Global News Toronto cover early-stage Bio Printer technology

An early-stage technology that may revolutionize the way burn victims are treated is generating considerable buzz in Toronto media this week. Globe and Mail reporter Robert Everett-Green wrote about the joint University of Toronto and Sunnybrook Health Sciences Centre project January 20 in "A 3-D machine that prints skin? How burn care could be revolutionized." Health reporter Beatrice Politi also covered the Bio Printer project for Global News Toronto January 21. Her video segment includes an interview with PhD student Lian Leng and ... Read more

Xconomy names Xagenic to 2012’s Biotech Startup Class

MI spin-off company one of 30 listed in North America and the United Kingdom Xconomy, a U.S.-based business news website, named Xagenic to its 2012 Biotech Startup Class. Luke Timmerman's article, published December 3, 2012, sited Xagenic as one of only 30 "exciting biotech startups" to raise significant venture capital (at least $5 million) in the life sciences sector. Xagenic, founded by Drs. Shana Kelley and Ted Sargent at the University of Toronto,  was also the only Canadian company named to the list. (more…) Read more

Shotlst: “Track changes” for the physical world

Shotlst is one of six inaugural UTEST companies; next UTEST application round to begin shortly What if you could turn on Microsoft Word’s “track changes” tool and apply it at will to the world around you? Sound like science fiction? Meet Matt Ratto, a professor in the University of T’s Faculty of Information, and Mike Borg, a recent graduate of the faculty. They’ve formed Shotlst, a new software company being incubated by the University of Toronto Early Stage Technology (UTEST) program. The central metaphor of ... Read more

Biotechnology Focus’ December issue covers MaRS Innovation projects and partnerships

MaRS Innovation's (MI) projects and partnerships earned three separate article mentions in the December 2012 issue of Biotechnology Focus, including: MI and UHN's partnership with Stem Cell Therapeutics was covered in the magazine's Dealmakers subsection. Read the write-up on the Biotechnology Focus website. Cellax, a licensable technology that may produce a nanotechonology-based cancer drug, was highlighted in the magazine's Business Corner section (read the write-up). Cellax is a joint project between MI and the Ontario Institute for Cancer Research. MaRS Innovation's ... Read more

Start-Up Snapshot: Flybits, OtoSim, ApneaDX, ScarX Therapeutics

Happy New Year. Here's a snapshot of some spin-off stories you may have missed over the holiday break: Flybits and Flybits Lite, the startup company's context-aware mobile technology that anyone can use, was mentioned in a Smithsonian.com article as one of six technologies changing the way the way humans live. ApneaDx was featured in a company profile post on the MaRS Blog: "ApneaDx: First we take Ontario, then we take the world." ScarX Therapeutics launched its website. OtoSim Inc. co-founder Dr. Vito ... Read more

Video: Dr. Raphael Hofstein’s interview with IBTimesTV

Technology reporter Alastair Charlton speaks to Dr. Raphael Hofstein, president and CEO of MaRS Innovation, about how Tech City in the U.K. can learn from Canada's hub for science, technology and social entrepreneurs. (more…) Read more

Bedside Clinical Systems featured in Philadelphia’s MedCity News

Bedside Clinical Systems (BCS) participated in Philadelphia's 2012 Canada-U.S. eHealth Summit on November 28. Twelve of the 65 participating companies were selected to pitch a group of over 100 chief medical information officers, chief information officers and chief medical officers from U.S. hospitals, along with venture capitalists and industry representatives. BCS's CEO Rajesh Sharma delivered a strong pitch and was interviewed for a story in MedCity News. (more…) Read more
Page 30 of 38« First...1020...2829303132...Last »